Rationale and Design of the SENECA (StEm cell iNjECtion in cAncer survivors) Trial

This is the first clinical trial using direct cardiac injection of cells for the treatment of AIC. If administration of allo-MSCs is found feasible and safe, SENECA will pave the way for larger phase II/III studies with therapeutic efficacy as the primary outcome.